Triple-negative breast cancer (TNBC) represents almost 15–20% of breast cancers [3] which can be distinguished by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) on breast cancer cells [1,4]. This evidence concerns the gene PGR and triple-negative breast carcinoma.